MOTS-c owns mitochondrial fitness and exercise biology; Sermorelin owns the sleep-and-GH recovery question. Start with the kind of recovery that is falling behind.
Soreness, sleep loss, and injury are different recovery problems
MOTS-c is the mitochondrial-fitness research injection. Sermorelin is the sleep-and-GH-axis injection. NAD+ is the direct-coenzyme routine, and B12 targets measured deficiency. Each owns a different reason that recovery can feel slow.
Before comparing vials, decide whether the problem is ordinary soreness, inadequate sleep, under-fueling, excessive training load, or a localized injury.
What belongs in this collection
- MOTS-c: best matched to mitochondrial signaling and metabolic-fitness research.
- Sermorelin injection: best matched to bedtime GH-signaling and recovery interest.
- NAD+ injection: best matched to a direct NAD and cellular-energy routine.
- B12 injection: best matched to a measured or strongly suspected B12 deficiency.
MOTS-c is a 16-amino-acid peptide encoded by a short open reading frame within mitochondrial 12S rRNA and detected in human skeletal muscle and circulation. Rebody's intended MOTS-c format is an injection vial. Do not collapse MOTS-c, Sermorelin injection, NAD+ injection, B12 injection into a shared “peptide” label: sprays, tablets, troches, and injections are different products with different evidence and instructions.
How the options differ
| Option | Biological question | Practical reason to choose it | Evidence boundary |
|---|---|---|---|
| MOTS-c injection | Mitochondrial and metabolic-fitness research | Closest experimental match to exercise biology | Human study measured endogenous exercise response; administered findings are from mice |
| Sermorelin injection | Bedtime GH-axis signaling | Current injection for sleep and overnight recovery interest | Wins the GH-axis question |
| NAD+ injection | NAD-dependent cellular energy biology | Three times weekly for 8 weeks | Wins for a defined direct-coenzyme course |
| Methylcobalamin B12 injection | Vitamin B12 deficiency | Best choice when low B12 explains fatigue | Wins when deficiency is the bottleneck |
The routine differs across MOTS-c, Sermorelin injection, NAD+ injection, B12 injection: injections require preparation, clean technique, storage, site rotation, supplies, and sharps disposal. Those differences do not prove better performance, but they can decide which option survives the first refill.
Why MOTS-c leads this search
Among MOTS-c, Sermorelin injection, NAD+ injection, B12 injection, MOTS-c leads because its molecule and evidence are closest to the shopper's question. The evidence is specific: In 10 young men, a stationary-bike session increased the body's own MOTS-c in skeletal muscle and serum. That was human exercise physiology, not treatment with a MOTS-c injection. Experiments that administered MOTS-c and improved physical-capacity or metabolic measures used mice. A recruiting Phase 2a trial plans 120 adults with prediabetes and overweight or obesity, 12 weeks of subcutaneous MOTS-c or placebo, and an OGTT-derived insulin-sensitivity endpoint. Results are not posted.
An alternative wins only when a measured deficiency or practical constraint changes the question. Claims from another molecule, model, or route do not make MOTS-c, Sermorelin injection, NAD+ injection, B12 injection equally supported.
What the research measured
The key distinction is administration. Cycling increased the participants’ own MOTS-c in a study of 10 young men; the experiments that administered MOTS-c and improved physical-capacity or metabolic measures were performed in mice. The 120-person Phase 2a trial is recruiting and has posted no results.
Slow recovery has at least four different meanings
Delayed-onset soreness, poor sleep, low readiness, and a tissue injury are not the same problem. Neither are glycogen depletion, under-fueling, anemia, endocrine changes, infection, or a training block that simply exceeds current capacity. The injection category should follow the cause.
Sermorelin is the most relevant injection when the question is bedtime GH-axis signaling. B12 wins when deficiency is present. NAD+ is a direct NAD routine. MOTS-c is the mitochondrial-fitness research option; it is not a proven soreness or injury treatment.
What recovery studies would need to measure
A useful trial would define the exercise bout and measure soreness, force recovery, range of motion, creatine kinase or another specified marker, sleep, and return to baseline across fixed time points. The cited MOTS-c work does not provide that trial.
Ten young men cycled and showed changes in endogenous MOTS-c. Administered MOTS-c improved capacity or metabolic measures in mice. The recruiting human Phase 2a trial centers on insulin sensitivity. None of those designs establishes faster recovery after lifting.
Compare injection routines honestly
NAD+ injection is 200 mg/mL in a 6 mL, 56-day package for $223.50 on the first two-month shipment, then $298 every two months ($149/month equivalent). B12 is 5 mg/mL in a 10 mL, 60-day package for $44.50 first month, then $89/month. Sermorelin injection is $109.50 first month, then $219/month for 30 days.
MOTS-c has no final package or price. Its eventual product page needs to show chemical form, concentration, volume, delivered amount, supply, cadence, storage, supplies, and refill timing together.
When recovery needs a different page
Pain localized to a tendon, ligament, joint, or recent procedure is not a general workout-recovery query. Worsening weakness, chest pain, fainting, dark urine, major swelling, fever, or neurologic symptoms need evaluation rather than another recovery product.
For ordinary training, stabilize sleep, protein and energy intake, hydration, and programming before judging a new intervention. Track time until usual performance returns, not merely whether a wearable readiness color changed.
Use the 24-, 48-, and 72-hour recovery test
Recovery becomes measurable when it is tied to a known session. At 24 hours, record soreness, sleep, appetite, resting heart rate, and whether normal movement is comfortable. At 48 hours, repeat the same training movement at a controlled load or note why it is not possible. At 72 hours, ask whether performance has returned to the person’s ordinary range. This separates a difficult workout from a persistent recovery problem.
The pattern changes the answer. Diffuse soreness after a new eccentric session is not the same as focal tendon pain. Poor sleep and an elevated resting heart rate after several hard days suggest accumulated load. Declining performance with irritability, illness, or persistent fatigue may call for reduced training and clinical evaluation, not another injectable. Swelling, deformity, inability to bear weight, neurologic symptoms, or worsening focal pain should leave the supplement-comparison lane entirely.
A recovery claim needs a measured recovery outcome, not a surrogate alone. A change in growth-hormone signaling is not proof of fewer sore days. A mitochondrial mechanism is not proof of faster return to training. An antioxidant mechanism is not proof of tissue repair. The study would need to measure the recovery outcome itself under a defined training or injury model.
When an injection is used for a separate established reason, keep the training record stable enough to judge it. Changing the program, sleep schedule, calories, and several compounds at once makes any recovery verdict guesswork.
Questions about recovery injections
Which peptide injection is best for muscle soreness?
None of the evidence cited here establishes a winner for post-exercise soreness. Sermorelin, MOTS-c, NAD+, and B12 answer different biological questions.
Is MOTS-c a tissue-repair peptide?
Not on the evidence reviewed here. Its research centers on mitochondrial signaling, metabolism, and physical capacity, not direct tendon or muscle-tear healing.
Can Sermorelin improve overnight recovery?
Sermorelin is the current GH-axis option in this set, but it is not a sedative and should not be described as a proven cure for poor sleep or workout soreness.
Is NAD+ injection proven to shorten recovery time?
No route-specific human evidence cited here establishes shorter workout recovery from NAD+ injection.
What should competitive athletes know?
MOTS-c is prohibited under the 2026 WADA list. Recovery intent does not make it permissible in tested sport.
Injection safety belongs here
Because this is an injection page, local pain, redness, swelling, bruising, and infection matter. Rotate sites and follow the exact label. Do not double a missed dose. Breathing difficulty, facial or throat swelling, fainting, severe chest pain, major neurologic symptoms, or serious-infection signs require urgent help.
Bottom line
MOTS-c is the peptide-first choice for mitochondrial fitness and exercise biology. Sermorelin leads the overnight GH-axis routine, NAD+ supplies direct NAD, and B12 wins when deficiency explains fatigue. Match the injection to the recovery problem instead of asking one product to solve all four.
Keep reading
- Peptide Treatments for Endurance and Training Consistency
- Peptides for Exercise Capacity and Metabolic Fitness
- Is MOTS-C an Exercise Mimetic? Human Data vs Mouse Treatment Results